Evidence map›Paper›PMID 25586960›Full record

ArticleStem cells (Dayton, Ohio)2015

Pak2 regulates hematopoietic progenitor cell proliferation, survival, and differentiation.

Yi Zeng, Hal E Broxmeyer, Karl Staser, Brahmananda Reddy Chitteti, Su-Jung Park, Seongmin Hahn, Scott Cooper, Zejin Sun, Li Jiang, XianLin Yang and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Stem cells (Dayton, Ohio), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Regulation of Cancer Metastasis by PAK2.International journal of molecular sciences · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Yi ZengDepartment of Pediatrics, Steele Children's Research Center, University of Arizona School of Medicine, Tucson, Arizona, USA.
Hal E Broxmeyer
Karl Staser
Brahmananda Reddy Chitteti
Su-Jung Park
Seongmin Hahn
Scott Cooper
Zejin Sun
Li Jiang
XianLin Yang
Jin Yuan
Rachelle Kosoff
George Sandusky
Edward F Srour
Jonathan Chernoff
D Wade Clapp
Indiana University – Purdue University Indianapolis · USFox Chase Cancer Center · USIndiana University School of MedicineUniversity of Arizona · USWashington University in St. Louis · US

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Jun Wan · 1999 to 2026
$59.3M
Project-005U54DK106846 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI Reuben Kapur, Karen Elizabeth Pollok · 2015 to 2026
$9.7M
MECHANISMS OF SYNERGISTIC REGULATION OF STEM/PROGENITORSR01HL056416 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI BROXMEYER, HAL E. · 1996 to 2017
$6.0M
Cytokine Enhancement of Myeloid Progenitor Cell SurvivalR01HL067384 · NHLBI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI BROXMEYER, HAL E. · 2001 to 2014
$4.6M
The Role of p21-Activated Kinases in Malignant MesotheliomaR01CA148805 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN, TESTA, JOSEPH R. · 2011 to 2020
$4.0M
Targeting the Kinome in Neurofibromatosis type 1R01CA142928 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI CHERNOFF, JONATHAN · 2010 to 2019
$3.9M
Regulating hematopoietic stem cells and hematopoiesis for clinical efficacyP30DK090948 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI BROXMEYER, HAL E., SROUR, EDWARD F · 2010 to 2014
$3.7M
Enhancing Engraftment of Cord Blood by CD26 InhibitionR01HL112669 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI BROXMEYER, HAL E., FARAG, SHERIF S · 2012 to 2016
$3.6M
Neurofibromatosis Type 1 Gene Regulates MyelopoiesisR01CA074177 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI CLAPP, DAVID W · 2002 to 2012
$3.6M
Cancer Biology Training ProgramT32CA111198 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI ROMAN, ANN · 2005 to 2009
$1.8M
NCI NIH HHS P30 CA082709NCI NIH HHS P30CA082709NCI NIH HHS R01 CA074177NCI NIH HHS R01 CA074177-15NCI NIH HHS R01 CA142928NCI NIH HHS R01CA142928NCI NIH HHS R01 CA148805NCI NIH HHS R01CA148805NCI NIH HHS T32 CA111198NCI NIH HHS T32CA111198NHLBI NIH HHS HL112669NHLBI NIH HHS R01 HL056416NHLBI NIH HHS R01 HL067384NHLBI NIH HHS R01 HL112669NHLBI NIH HHS R01HL56416NHLBI NIH HHS R01HL67384NIDDK NIH HHS P01DK090948NIDDK NIH HHS P30 DK090948NIDDK NIH HHS U54 DK106846
6 · The paper itself

Abstract

p21-Activated kinase 2 (Pak2), a serine/threonine kinase, has been previously shown to be essential for hematopoietic stem cell (HSC) engraftment. However, Pak2 modulation of long-term hematopoiesis and lineage commitment remain unreported. Using a conditional Pak2 knockout mouse model, we found that disruption of Pak2 in HSCs induced profound leukopenia and a mild macrocytic anemia. Although loss of Pak2 in HSCs leads to less efficient short- and long-term competitive hematopoiesis than wild-type cells, it does not affect HSC self-renewal per se. Pak2 disruption decreased the survival and proliferation of multicytokine stimulated immature progenitors. Loss of Pak2 skewed lineage differentiation toward granulocytopoiesis and monocytopoiesis in mice as evidenced by (a) a three- to sixfold increase in the percentage of peripheral blood granulocytes and a significant increase in the percentage of granulocyte-monocyte progenitors in mice transplanted with Pak2-disrupted bone marrow (BM); (b)Pak2-disrupted BM and c-kit(+) cells yielded higher numbers of more mature subsets of granulocyte-monocyte colonies and polymorphonuclear neutrophils, respectively, when cultured in the presence of granulocyte-macrophage colony-stimulating factor. Pak2 disruption resulted, respectively, in decreased and increased gene expression of transcription factors JunB and c-Myc, which may suggest underlying mechanisms by which Pak2 regulates granulocyte-monocyte lineage commitment. Furthermore, Pak2 disruption led to (a) higher percentage of CD4(+) CD8(+) double positive T cells and lower percentages of CD4(+) CD8(-) or CD4(-) CD8(+) single positive T cells in thymus and (b) decreased numbers of mature B cells and increased numbers of Pre-Pro B cells in BM, suggesting defects in lymphopoiesis.

Indexed as

Cell DifferentiationAnemia, MacrocyticAnimalsApoptosisCell ProliferationCell SurvivalGene DeletionGene Expression RegulationHematopoiesisHematopoietic Stem CellsLeukopeniaLymphopoiesisMice, KnockoutMyeloid Cellsp21-Activated KinasesPhenotypep21-Activated KinasesPak2 protein, mouseTranscription FactorsHematopoietic progenitor cellLymphopoiesisMyelopoiesisPak2

Identifiers

PMID25586960
PMCPMC4409559
OpenAlexW2142448409

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.